Research ExplorerPublicationsOther-cause mortality and access to care in metastatic renal...

Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity

Standard

Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. / Sorce, Gabriele; Hoeh, Benedikt; Hohenhorst, Lukas; Panunzio, Andrea; Tappero, Stefano; Tian, Zhe; Larcher, Alessandro; Capitanio, Umberto; Tilki, Derya; Terrone, Carlo; Chun, Felix K H; Antonelli, Alessandro; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

In: UROL ONCOL-SEMIN ORI, Vol. 40, No. 11, 11.2022, p. 493.e9-493.e16.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sorce, G, Hoeh, B, Hohenhorst, L, Panunzio, A, Tappero, S, Tian, Z, Larcher, A, Capitanio, U, Tilki, D, Terrone, C, Chun, FKH, Antonelli, A, Saad, F, Shariat, SF, Montorsi, F, Briganti, A & Karakiewicz, PI 2022, 'Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity', UROL ONCOL-SEMIN ORI, vol. 40, no. 11, pp. 493.e9-493.e16. https://doi.org/10.1016/j.urolonc.2022.06.022

APA

Sorce, G., Hoeh, B., Hohenhorst, L., Panunzio, A., Tappero, S., Tian, Z., Larcher, A., Capitanio, U., Tilki, D., Terrone, C., Chun, F. K. H., Antonelli, A., Saad, F., Shariat, S. F., Montorsi, F., Briganti, A., & Karakiewicz, P. I. (2022). Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. UROL ONCOL-SEMIN ORI, 40(11), 493.e9-493.e16. https://doi.org/10.1016/j.urolonc.2022.06.022

Vancouver

Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z et al. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. UROL ONCOL-SEMIN ORI. 2022 Nov;40(11):493.e9-493.e16. https://doi.org/10.1016/j.urolonc.2022.06.022

Bibtex

@article{089dbcb705fa44b692a1440e73d1b406,
title = "Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity",
abstract = "BACKGROUND: We tested for other-cause mortality (OCM) differences according to race/ethnicity in metastatic renal cell carcinoma (mRCC). Such differences may affect treatment considerations.METHODS: Within the Surveillance, Epidemiology, and End Results Research Plus repository (2000-2018), we identified clear cell (ccmRCC) and non-clear cell (non-ccmRCC) mRCC patients and stratified according to race/ethnicity: Caucasian vs. Hispanic vs. African American vs. Asian. Poisson smoothed cumulative incidence plots and competing risks regression (CRR) models addressing OCM, after adjustment for cancer-specific mortality , were fitted. Subsequently, multivariable logistic regression models tested access to cytoreductive nephrectomy (CNT) and systemic therapy (ST).RESULTS: Of 10,958 ccmRCC patients, 7,892 (72%), 1,743 (16%), 688 (6%), and 635 (6%) were Caucasian, Hispanic, African American, and Asian, respectively. Of 1,239 non-ccmRCC patients, 799 (64%), 106 (9%), 278 (22%), and 56 (5%) were Caucasian, Hispanic, African American, and Asian, respectively. In multivariable CRR models, OCM was higher in African Americans vs. Caucasians in ccmRCC (HR:1.55; CI:1.19-2.01; P < 0.001) and in non-ccmRCC (HR:1.54; CI:1.01-2.35; P = 0.04). In multivariable logistic regression models, African Americans with ccmRCC were less likely to undergo CNT (OR:0.72, CI:0.60-0.86; P < 0.001), but more likely to undergo ST (OR:1.34, CI:1.11-1.61; P = 0.002).CONCLUSIONS: In this retrospective analysis, African Americans with ccmRCC and non-ccmRCC exhibited higher OCM than Caucasians. Based on higher OCM, African Americans were less likely to undergo CNT, but more likely to benefit from ST.",
keywords = "Humans, Carcinoma, Renal Cell/pathology, Kidney Neoplasms/pathology, Ethnicity, Retrospective Studies, SEER Program, Health Services Accessibility",
author = "Gabriele Sorce and Benedikt Hoeh and Lukas Hohenhorst and Andrea Panunzio and Stefano Tappero and Zhe Tian and Alessandro Larcher and Umberto Capitanio and Derya Tilki and Carlo Terrone and Chun, {Felix K H} and Alessandro Antonelli and Fred Saad and Shariat, {Shahrokh F} and Francesco Montorsi and Alberto Briganti and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2022",
month = nov,
doi = "10.1016/j.urolonc.2022.06.022",
language = "English",
volume = "40",
pages = "493.e9--493.e16",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity

AU - Sorce, Gabriele

AU - Hoeh, Benedikt

AU - Hohenhorst, Lukas

AU - Panunzio, Andrea

AU - Tappero, Stefano

AU - Tian, Zhe

AU - Larcher, Alessandro

AU - Capitanio, Umberto

AU - Tilki, Derya

AU - Terrone, Carlo

AU - Chun, Felix K H

AU - Antonelli, Alessandro

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2022/11

Y1 - 2022/11

N2 - BACKGROUND: We tested for other-cause mortality (OCM) differences according to race/ethnicity in metastatic renal cell carcinoma (mRCC). Such differences may affect treatment considerations.METHODS: Within the Surveillance, Epidemiology, and End Results Research Plus repository (2000-2018), we identified clear cell (ccmRCC) and non-clear cell (non-ccmRCC) mRCC patients and stratified according to race/ethnicity: Caucasian vs. Hispanic vs. African American vs. Asian. Poisson smoothed cumulative incidence plots and competing risks regression (CRR) models addressing OCM, after adjustment for cancer-specific mortality , were fitted. Subsequently, multivariable logistic regression models tested access to cytoreductive nephrectomy (CNT) and systemic therapy (ST).RESULTS: Of 10,958 ccmRCC patients, 7,892 (72%), 1,743 (16%), 688 (6%), and 635 (6%) were Caucasian, Hispanic, African American, and Asian, respectively. Of 1,239 non-ccmRCC patients, 799 (64%), 106 (9%), 278 (22%), and 56 (5%) were Caucasian, Hispanic, African American, and Asian, respectively. In multivariable CRR models, OCM was higher in African Americans vs. Caucasians in ccmRCC (HR:1.55; CI:1.19-2.01; P < 0.001) and in non-ccmRCC (HR:1.54; CI:1.01-2.35; P = 0.04). In multivariable logistic regression models, African Americans with ccmRCC were less likely to undergo CNT (OR:0.72, CI:0.60-0.86; P < 0.001), but more likely to undergo ST (OR:1.34, CI:1.11-1.61; P = 0.002).CONCLUSIONS: In this retrospective analysis, African Americans with ccmRCC and non-ccmRCC exhibited higher OCM than Caucasians. Based on higher OCM, African Americans were less likely to undergo CNT, but more likely to benefit from ST.

AB - BACKGROUND: We tested for other-cause mortality (OCM) differences according to race/ethnicity in metastatic renal cell carcinoma (mRCC). Such differences may affect treatment considerations.METHODS: Within the Surveillance, Epidemiology, and End Results Research Plus repository (2000-2018), we identified clear cell (ccmRCC) and non-clear cell (non-ccmRCC) mRCC patients and stratified according to race/ethnicity: Caucasian vs. Hispanic vs. African American vs. Asian. Poisson smoothed cumulative incidence plots and competing risks regression (CRR) models addressing OCM, after adjustment for cancer-specific mortality , were fitted. Subsequently, multivariable logistic regression models tested access to cytoreductive nephrectomy (CNT) and systemic therapy (ST).RESULTS: Of 10,958 ccmRCC patients, 7,892 (72%), 1,743 (16%), 688 (6%), and 635 (6%) were Caucasian, Hispanic, African American, and Asian, respectively. Of 1,239 non-ccmRCC patients, 799 (64%), 106 (9%), 278 (22%), and 56 (5%) were Caucasian, Hispanic, African American, and Asian, respectively. In multivariable CRR models, OCM was higher in African Americans vs. Caucasians in ccmRCC (HR:1.55; CI:1.19-2.01; P < 0.001) and in non-ccmRCC (HR:1.54; CI:1.01-2.35; P = 0.04). In multivariable logistic regression models, African Americans with ccmRCC were less likely to undergo CNT (OR:0.72, CI:0.60-0.86; P < 0.001), but more likely to undergo ST (OR:1.34, CI:1.11-1.61; P = 0.002).CONCLUSIONS: In this retrospective analysis, African Americans with ccmRCC and non-ccmRCC exhibited higher OCM than Caucasians. Based on higher OCM, African Americans were less likely to undergo CNT, but more likely to benefit from ST.

KW - Humans

KW - Carcinoma, Renal Cell/pathology

KW - Kidney Neoplasms/pathology

KW - Ethnicity

KW - Retrospective Studies

KW - SEER Program

KW - Health Services Accessibility

U2 - 10.1016/j.urolonc.2022.06.022

DO - 10.1016/j.urolonc.2022.06.022

M3 - SCORING: Journal article

C2 - 35907705

VL - 40

SP - 493.e9-493.e16

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 11

ER -